In this issue:
OS with amivantamab-lazertinib in EGFR-mutated advanced NSCLC
Patients’ and physicians’ preferred maintenance treatments for advanced NSCLC
RT-free pembrolizumab-chemotherapy for locally advanced NSCLC with PD-L1 TPS ≥50%
Surrogate endpoints for OS in extensive-stage SCLC
First-line lorlatinib vs. alectinib for ALK-rearranged advanced NSCLC
Afatinib-pemetrexed-carboplatin for osimertinib-refractory EGFR-mutated nonsquamous advanced NSCLC
Atezolizumab-carboplatin-nabpaclitaxel for TTF-1-ve advanced nonsquamous NSCLC
Surgical outcomes with neoadjuvant (+chemotherapy)/adjuvant durvalumab in resectable NSCLC
Datopotamab deruxtecan for EGFR-mutated NSCLC
Docetaxel for KRASG12C-mutated NSCLC in immune checkpoint inhibitor era
Please login below to download this issue (PDF)